Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02019602 · ClinicalTrials.gov registry record · Phase 1
A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta
A Phase 1 study, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT02019602 is a Phase 1 study that has completed, run by UCB Biosciences. The registered enrollment target is 37 participants.
The verdict
NCT02019602, a Phase 1 study, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
The primary purpose is to assess whether there is transfer of Certolizumab Pegol (CZP) from pregnant women receiving treatment with Cimzia® across the placenta to infants by evaluating the concentration of CZP in the plasma of infants at birth.
Interventions
- BIOLOGICAL Certolizumab Pegol
- PROCEDURE Blood sampling from mother
- PROCEDURE Blood sampling from infant
- PROCEDURE Blood sampling from umbilical cord
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2014-01 |
| Est. Completion | 2016-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02019602
The ClinicalTrials.gov registry entry for NCT02019602 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biosciences, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Certolizumab Pegol is the first listed.
NCT02019602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02019602 about?
NCT02019602 is a clinical study titled "A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta". The primary purpose is to assess whether there is transfer of Certolizumab Pegol (CZP) from pregnant women receiving treatment with Cimzia® across the placenta to infants by evaluating the concentration of CZP in the plasma of infants at birth.
What is the current status of trial NCT02019602?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2014-01. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02019602?
The interventions under investigation include: Certolizumab Pegol (BIOLOGICAL), Blood sampling from mother (PROCEDURE), Blood sampling from infant (PROCEDURE), Blood sampling from umbilical cord (PROCEDURE).
Who is sponsoring clinical trial NCT02019602?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.